Get started
Live feed
·
PRReleasevia Quantisnow
Elevation Oncology Inc. logo

Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical Group

ByQuantisnow·Wall Street's wire, on your screen.
Stocks in this Quantisnow insight
Quantisnow market dataNASDAQ
Elevation Oncology Inc. logo
ELEV
Elevation Oncology Inc.
Market cap
30-day
Sector
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Listed since
2021
Follow ELEVFull ELEV profile on Quantisnow

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ELEV (Elevation Oncology Inc.) and more on Quantisnow.